Hematologic Diseases: Clinical Trials

289 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

289 unknown. 289 Phase 3, 79 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3289Unknown 289
Phase 279Unknown 79

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 289 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Maternal Under-nutrition and Effect of Amaranth Grain Flat-bread on Anemia
Amaranth grain flat bread - Maternal Anemia in Pregnancy, Before Birth, Maternal; Malnutrition, Affecting Fetus
Phase 3UnknownHawassa University3062024-08-102024-08-02
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
avatrombopag, Placebo - Thrombocytopenia, Stem Cell Transplant Complications
Phase 2 / Phase 3UnknownPeking University People's Hospital1422024-05-132024-10-01
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Nelarabine injection - T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
Phase 3UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.832024-05-012024-05-30
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
DEC3-VEN - Acute Myeloid Leukemia, Adult
Phase 2 / Phase 3UnknownThe Second Affiliated Hospital of Kunming Medical University402024-03-012024-02-29
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
Liposomal cytarabine-daunorubicin for injection, 7+3 (cytarabine and daunorubicin) - High-risk (Secondary) Acute Myeloid Leukemia
Phase 3UnknownCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1202024-01-012023-12-28
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
BCD-264, Darzalex - Multiple Myeloma
Phase 3UnknownBiocad2522023-12-212024-03-06
Lapelga vs Gastrofil
Grastofil®, Lapelga - Multiple Myeloma, Lymphoma
Phase 3UnknownLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's742023-11-012023-11-03
EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD
Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron), Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron), Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron) - Inflammatory Bowel Disease, Iron Deficiency Anemia
Phase 3UnknownLiverpool University Hospitals NHS Foundation Trust302023-10-202024-03-20
SMILES: Study of Montelukast in Sickle Cell Disease
Montelukast, Oral Placebo - Anemia, Sickle Cell, Sleep-Disordered Breathing
Phase 2 / Phase 3UnknownGreat Ormond Street Hospital for Children NHS Foundation Trust2002023-10-162023-11-01
CURATE.AI Optimized Modulation for Multiple Myeloma
Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma
Phase 2 / Phase 3UnknownNational University Hospital, Singapore202023-09-102023-09-06
Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer
Ascorbate, Nab paclitaxel, Gemcitabine - Metastatic Pancreatic Adenocarcinoma
Phase 3UnknownFudan University1002023-08-202025-08-07
A Study to Compare Liposomal Iron With Ferrous Ascorbate in the Treatment of Iron Deficiency Anemia in Children
Ferric Pyrophosphate Liposomal, ferrous ascorbate - Nutritional Anemia
Phase 3UnknownAll India Institute of Medical Sciences962023-08-012023-07-24
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
"Emicizumab", "HEMLIBRA®" - Severe Hemophilia A Without Inhibitor, Joint Bleed
Phase 2 / Phase 3UnknownChulalongkorn University152023-06-222024-03-05
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Erythropoietin - Anemia, Neoplasms
Phase 3UnknownBlau Farmaceutica S.A.3202023-05-012023-01-30
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
Ferric Derisomaltose Injection, Darbepoetin Alfa Injection - Anemia
Phase 3UnknownHallym University Medical Center3122023-03-012023-03-15
A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors
Shengxuening Tablet, Ferrous succinate - Hematological Malignancy, Cancer-Related Anemia
Phase 3UnknownZhongnan Hospital1682023-02-072023-08-25
Tacrolimus for Thrombocytopenia in SS
Hydroxychloroquine, Tacrolimus - Sjogren Syndrome With Other Organ Involvement
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital542023-02-012023-01-10
Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS
Prednisolone, Tacrolimus - Sjogren Syndrome With Other Organ Involvement
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1102023-02-012023-01-23
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Herombopag - Immune Thrombocytopenia
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.1172023-01-232023-01-17
Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia
Metformin - Fanconi Anemia
Phase 3UnknownAin Shams University302022-10-052024-07-25

Showing 20 of 289. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (51)  ·  Multiple Myeloma (38)  ·  Leukemia (35)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (29)  ·  Anemia (24)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (19)  ·  Purpura, Thrombocytopenic, Idiopathic (17)  ·  Myelodysplastic Syndromes (16)  ·  Lymphoma (15)  ·  Thrombocytopenia (14)  ·  Lymphoma, Follicular (13)  ·  Hematologic Neoplasms (12)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11)  ·  Anemia, Sickle Cell (10)  ·  Lymphoma, Large B-Cell, Diffuse (10)

Broader conditions

Hemic and Lymphatic Diseases (289)  ·  Neoplasms (165)  ·  Neoplasms by Histologic Type (159)  ·  Immune System Diseases (111)  ·  Immunoproliferative Disorders (86)  ·  Lymphoproliferative Disorders (86)  ·  Leukemia (84)  ·  Pathological Conditions, Signs and Symptoms (84)  ·  Pathologic Processes (77)  ·  Hemorrhagic Disorders (74)  ·  Leukemia, Myeloid (72)  ·  Cardiovascular Diseases (55)  ·  Lymphatic Diseases (54)  ·  Vascular Diseases (53)

Interventions

Cytarabine (33)  ·  Cyclophosphamide (30)  ·  Dexamethasone (28)  ·  Idarubicin (18)  ·  Decitabine (17)  ·  Etoposide (17)  ·  Daunorubicin (14)  ·  Radiotherapy (13)  ·  Doxorubicin (12)  ·  Busulfan (11)  ·  Methotrexate (11)  ·  Vincristine (11)  ·  Melphalan (10)  ·  Filgrastim (9)  ·  Mercaptopurine (9)

Sponsors

Nanfang Hospital, Southern Medical University (14)  ·  Assistance Publique - Hôpitaux de Paris (13)  ·  European Organisation for Research and Treatment of Cancer - EORTC (10)  ·  The First Affiliated Hospital of Soochow University (10)  ·  Ain Shams University (8)  ·  Shandong University (7)  ·  Medical Research Council (5)  ·  Peking University People's Hospital (5)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4)  ·  Federal Research Institute of Pediatric Hematology, Oncology and Immunology (4)  ·  Peking Union Medical College Hospital (3)  ·  Tehran University of Medical Sciences (3)  ·  All India Institute of Medical Sciences (2)  ·  Assiut University (2)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2)

Countries

China (87)  ·  United Kingdom (28)  ·  France (26)  ·  Germany (23)  ·  Italy (19)  ·  Belgium (15)  ·  United States (14)  ·  Netherlands (13)  ·  Austria (11)  ·  Brazil (10)  ·  Czechia (10)  ·  Israel (10)  ·  Canada (9)  ·  Egypt (9)  ·  Russia (9)

Top investigators

Qifa Liu (4)  ·  Ming Hou, Dr (3)  ·  Qifa Liu, MD (3)  ·  Xiaowen Tang, Ph.D. (3)  ·  Fernando Dimeo, MD (2)  ·  Galina Novichkova (2)  ·  Graham Jackson, MD (2)  ·  Han Yue, Ph.D (2)  ·  Lei Li, M.D. (2)  ·  Mohsen S Elalfy, professor (2)  ·  Ruediger Hehlmann, MD (2)  ·  Samir G Agrawal, MD, PhD (2)  ·  Stephen J. Proctor, MD, FRCP, FRCPath (2)  ·  Theo De Witte, MD, PhD (2)  ·  William A. Wegener, MD, PhD (2)

Results publications

PMID 34932836, PMID 41114449, PMID 15812540, PMID 20940381, PMID 21195303, PMID 25753432, PMID 29926156, PMID 30523055, PMID 33242441, PMID 35244208, PMID 38780066, PMID 11137554, PMID 11231246, PMID 11675328, PMID 12111109, PMID 12153596, PMID 12510709, PMID 12694250, PMID 12780755, PMID 15010373, PMID 15131807, PMID 15189396, PMID 15711856, PMID 15801953, PMID 15842354, PMID 15952999, PMID 16103468, PMID 16155013, PMID 16427380, PMID 16475046, PMID 17360989, PMID 17366834, PMID 17859247, PMID 18083847, PMID 18094721, PMID 18166796, PMID 18182574, PMID 18239868, PMID 18276714, PMID 18358930, PMID 19005182, PMID 19095121, PMID 19166855, PMID 19242495, PMID 19387663, PMID 19826132, PMID 19880501, PMID 19952380, PMID 20006130, PMID 20011381

NIH funding

2005 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2019 (1)